Topic:

M&A

Latest Headlines

Latest Headlines

Teva wants Mylan wants Perrigo, and the pundits go mad with opinions

Rumors of a Teva-Mylan merger have swirled for weeks, and now that Teva's bid has actually arrived, the talk is heating up even more. Everyone has an opinion--Mylan and Teva included--and those opinions are all over the map. Strategic or not? Legally possible or not? At what price might Mylan be willing to talk? And could Mylan persuade the reluctant Perrigo to take its (defensive) $29 billion offer? 

Deep discounts allow Remicade biosimilar to grab 50% of Norway's market

Conventional thinking is that the complexity of biosimilars will keep their discounts to just 20% to 30% of the branded price. Think again. In Norway a biosimilar of Merck's arthritis blockbuster Remicade is going for a discount of nearly 70%, upsetting conventional wisdom and competitors.

Perrigo spurned Mylan's $29B offer, but would a bigger one do?

Bad news for Mylan if it wants to avoid a $40 billion takeover by generics rival Teva: Its own acquisition prospect, Ireland's Perrigo, isn't interested in getting together.

Think the pharma M&A party will start winding down? Think again

Investors like pharma M&A. Drugmakers have money--or access to it. Ergo, look for the dealmaking frenzy to continue, a Morgan Stanley equity strategist says. The pharma industry accounted for 45% of U.S. M&A so far this quarter, Bloomberg reports, and at least 20% of the value of all offers over the last two quarters.

Boosted by Opsumit, one-time target Actelion is ready to make its own deals

Actelion hasn't been too keen on becoming an M&A target lately. But if it's the one in the driver's seat? Bring on the deals, CFO André Muller says.

Does a $45B Vertex buyout make sense for Gilead? Porges says heck yes

Bernstein's Geoffrey Porges has run the numbers on what a Gilead takeover of Vertex would look like. And he loves what he sees.

Ready for a Teva-Mylan scrap? It's here. Teva finally launches its $40B takeover bid

The rumors are true: Teva does indeed have eyes for Mylan. And after months of speculation, its bid is here.

Surging Actelion is on the hunt for buyouts amid 'M&A frenzy'

Fueled by strong sales for its latest cardio drug and a promising pipeline, Switzerland's Actelion says it's on the lookout for acquisitions but remains wary of paying the big premiums that have become commonplace in pharma.

Satisfying EU regulators on Zimmer's Biomet deal, Italian orthopedics company to buy trio of divested products

Lima Corporate, an established Italian orthopedics company, is buying the three product lines from Zimmer and Biomet that the European Commission had last month required them to sell to complete their acquisition deal. The deal complements its own newly launched total knee system.

Daiichi Sankyo cashing out after merging Ranbaxy with Sun

Daiichi Sankyo has had enough of trying to make money in the Indian generic drug industry. The Japanese drugmaker, which faces patent cliff issues, is selling off its stake in Sun Pharmaceutical just weeks after it closed on the all-stock deal selling Ranbaxy Laboratories to Sun for $3.2 billion.